Posted On: 11/19/2014 6:14:39 PM
Post# of 30066
No one on this board can estimate a "reasonable" sale price, since we don't have realistic LymPro revenue projections. No one should place any confidence in Jason's figure. The company has the realistic projections, after speaking to KOLs and researchers for several years on their interest.
Give that, I will toss out a minimum expectation of $100M sale price, but I would not be surprised if it is valued much higher. It will be a trade-off of up-front payment vs. royalty percentage. It might be $50M with 30% royalty, or $200M with 10% royalty. Whatever it turns out to be, it will be the first solid validation of the business model of the holding company, as stated in the CC. And it appears management is more than willing to return a sizable portion of that gain back to shareholders in the form of cash or shares in the spin-off company.
Give that, I will toss out a minimum expectation of $100M sale price, but I would not be surprised if it is valued much higher. It will be a trade-off of up-front payment vs. royalty percentage. It might be $50M with 30% royalty, or $200M with 10% royalty. Whatever it turns out to be, it will be the first solid validation of the business model of the holding company, as stated in the CC. And it appears management is more than willing to return a sizable portion of that gain back to shareholders in the form of cash or shares in the spin-off company.
(0)
(0)
